Amgen Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Amgen Inc. (AMGN) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of -$71.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-25.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2011-02-25
- Amgen Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2010 was -$71.00M.
- Amgen Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2009 was -$11.00M, a 112.79% decline from fiscal 2008.
- Amgen Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2008 was $86.00M, a 230.77% increase from fiscal 2007.
- Amgen Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2007 was $26.00M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2010-12-31 | -$71.00M 10-K · filed 2011-02-25 |
| 2009-12-31 | -$11.00M 10-K · filed 2011-02-25 |
| 2008-12-31 | $86.00M 10-K · filed 2011-02-25 |
| 2007-12-31 | $26.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |